Murray Clare S
School of Translational Medicine, Respiratory Group, University of Manchester, ERC, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
Curr Opin Allergy Clin Immunol. 2008 Feb;8(1):77-81. doi: 10.1097/ACI.0b013e3282f41769.
Asthma is characterised by variable airflow obstruction, airway inflammation and hyper-responsiveness. Persistent inflammation is thought to lead to 'remodelling' of the airway, which in turn leads to the progressive loss of lung function seen in asthmatics. It would appear logical that anti-inflammatory drugs such as inhaled corticosteroids (ICS) would influence the natural history of asthma by reducing inflammation, subsequent remodelling, and thus preventing the decline in lung function. This review will summarise the effects of ICS on the secondary prevention of asthma, lung function and remodelling.
Many published studies show a reduction in airway inflammation, improvement in clinical symptoms and prebronchodilator lung function whilst taking ICS. Few studies, however, examine their effect on the natural history of asthma. Several recent studies have targeted very young children with asthma using ICS, and despite their differing target populations and treatment strategies, have failed to show any difference in lung function. Studies in adults with mild persistent asthma show similar findings. ICS appear to reverse some of the processes involved in airway remodelling, but not all.
Although ICS are effective in controlling symptoms they do not appear to alter the natural history of asthma.
哮喘的特征是气流受限、气道炎症和高反应性。持续性炎症被认为会导致气道“重塑”,进而导致哮喘患者肺功能逐渐丧失。吸入性糖皮质激素(ICS)等抗炎药物通过减轻炎症、减少随后的重塑,从而防止肺功能下降来影响哮喘的自然病程,这似乎是合乎逻辑的。本综述将总结ICS对哮喘二级预防、肺功能和重塑的影响。
许多已发表的研究表明,在使用ICS期间,气道炎症减轻,临床症状改善,支气管扩张剂前肺功能改善。然而,很少有研究考察其对哮喘自然病程的影响。最近有几项研究针对患有哮喘的幼儿使用ICS,尽管其目标人群和治疗策略不同,但均未显示肺功能有任何差异。对轻度持续性哮喘成人的研究也有类似发现。ICS似乎能逆转气道重塑过程中的一些环节,但并非全部。
尽管ICS能有效控制症状,但似乎并不能改变哮喘的自然病程。